A 24-Week, Blinded, Randomized, Placebo-Controlled Dose-Ranging Trial of Nasal PYY3-36 for Weight Loss in Healthy Obese Patients
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2008
At a glance
- Drugs Peptide YY 3-36 (Primary) ; Sibutramine
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2008 Status changed from in progress to completed.
- 01 Aug 2008 Primary endpoint not met, as reported in a MDRNA media release.
- 08 Jan 2008 Status change from recruiting to in progress, from Nastech Pharmaceutical Company media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History